Here are the DEF 14A proxy statements from Indaptus Therapeutics, Inc. (INDP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow INDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INDP filings page.
Indaptus Therapeutics, Inc. is asking stockholders to vote at its 2026 annual meeting, to be held virtually on August 10, 2026. Holders of 113,242,324 shares of common stock outstanding as of June 12, 2026 may vote.
Stockholders will elect three Class II directors to serve until the 2029 meeting, ratify Haskell & White LLP as independent auditor for 2026, and approve a new 2026 Equity Incentive Plan. The plan initially reserves 13,324,232 shares, with an automatic annual increase of 5% of shares outstanding from 2027 through 2031, while shutting off future grants and the evergreen feature under the 2021 plan.
The proxy also details 2025 executive pay, including total compensation of $2,197,171 for Co‑CEO Jeffrey A. Meckler, $1,953,870 for COO Walt A. Linscott and $1,691,286 for Chief Scientific Officer Michael J. Newman, as well as cash-and-stock payments under 2025 modification agreements tied to a recapitalization.
Indaptus Therapeutics has called a February 26, 2026 special meeting to ask stockholders to approve a transformative recapitalization built around a recent $6.0 million preferred stock investment by David E. Lazar. The company sold 300,000 Series AA and 700,000 Series AAA Convertible Preferred shares at $6.00 each; after stockholder approval these can convert into 111.0 million common shares. Based on 2,242,324 common shares outstanding as of January 21, 2026, full conversion would give the new investor about 96.4% of the fully diluted common, sharply diluting existing holders and concentrating voting power. Proposals also include electing two Lazar nominees to the board, authorizing a reverse stock split in a 1‑for‑2 to 1‑for‑199 range, increasing authorized common from 200,000,000 up to 1,000,000,000 shares, permitting stockholder action by written consent, and related Nasdaq change of control and issuance approvals.